{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:16:25Z","timestamp":1740179785914,"version":"3.37.3"},"reference-count":10,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"1","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["RAM"],"abstract":"<jats:p>Antecedentes: El p\u00e9nfigo es una enfermedad autoinmune cr\u00f3nica y recalcitrante que afecta piel y mucosas. El tratamiento de primera l\u00ednea son los corticosteroides sist\u00e9micos, aunque hay pacientes refractarios a estos y a otros inmunosupresores. Como alternativa, desde el a\u00f1o 2000 se ha utilizado el rituximab con buenos resultados, pero sin informaci\u00f3n de su comportamiento en poblaci\u00f3n mexicana. Objetivo: Evaluar la respuesta cl\u00ednica al tratamiento con rituximab en pacientes mexicanos con p\u00e9nfigo. M\u00e9todos: Se trat\u00f3 de un estudio transversal, retrospectivo en un hospital de tercer nivel, en el que se incluyeron pacientes con p\u00e9nfigo moderado-severo tratados con rituximab entre 2007 y 2020. Resultados: Se obtuvieron seis expedientes de pacientes con diagn\u00f3stico de p\u00e9nfigo, cuatro presentaron la variedad vulgar y dos, la variedad foli\u00e1cea; todos recibieron tratamiento sist\u00e9mico inmunosupresor previo al rituximab. Los seis pacientes tuvieron remisi\u00f3n de la enfermedad en un promedio de 12.5 semanas. Conclusi\u00f3n: El rituximab para el tratamiento de pacientes con p\u00e9nfigo moderado-severo refractario a tratamiento inmunosupresor demostr\u00f3 ser de gran utilidad y logr\u00f3 un control de la enfermedad a mediano plazo, sin efectos adversos severos ni idiosincr\u00e1ticos en la poblaci\u00f3n mexicana estudiada.<\/jats:p>","DOI":"10.29262\/ram.v68i1.826","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T01:02:27Z","timestamp":1624237347000},"page":"7-11","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab como tratamiento de p\u00e9nfigo refractario en pacientes mexicanos"],"prefix":"10.29262","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7287-2399","authenticated-orcid":false,"given":"Samantha","family":"Cruz-Meza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2313-0062","authenticated-orcid":false,"given":"Le\u00f3n Felipe","family":"Ruiz-Arriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4119-6479","authenticated-orcid":false,"given":"Mar\u00eda Teresa","family":"Barr\u00f3n-Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Estrada-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Schmidt E. Rituximab as first-line treatment of pemphigus. Lancet 2017;389(10083):1956-1958. DOI: 10.1016\/S0140-6736(17)30787-0","DOI":"10.1016\/S0140-6736(17)30787-0"},{"key":"ref1","unstructured":"Federaci\u00f3n Mexicana de Enfermedades Raras [Internet]. M\u00e9xico: P\u00e9nfigo vulgar; 2016. [Consultado 2020 Nov 01]. Disponible en: http:\/\/www.femexer.org\/8847\/penfigo-vulgar\/"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, Setterfield JF, Yesudian PD. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017.Br J Dermatol 2017;177(5):1170-1201. DOI: 10.1111\/bjd.15930","DOI":"10.1111\/bjd.15930"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Daneshpazhooh M, Balighi K, Mahmoudi H, Tavakolpour S, Abedini R, Soori T, et al. Iranian guideline for rituximab therapy in pemphigus patients. Dermatol Ther. 2019;32(5):e13016. DOI: 10.1111\/dth.13016","DOI":"10.1111\/dth.13016"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kridin K, Zelber-Sagi S, Bergman R. Risk factors for lethal outcome in patients with pemphigus: a retrospective cohort study. Eur J Dermatol. 2018;28(1):26-37. DOI: 10.1684\/ejd.2018.3252","DOI":"10.1684\/ejd.2018.3252"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Kridin K, Sagi SZ, Bergman R. Mortality and cause of death in patients with pemphigus. Acta Derm Venereol. 2017;97(5):607-611. DOI: 10.2340\/00015555-2611","DOI":"10.2340\/00015555-2611"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Mimouni D, Bar H, Gdalevich M, Katzenelson V, David M. Pemphigus, analysis of 155 patients. J Eur Acad Dermatol Venereol. 2010;24:947-952. DOI: 10.1111\/j.1468-3083.2010.03584.x","DOI":"10.1111\/j.1468-3083.2010.03584.x"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Jelti L, Prost-Squarcioni C, Ingen-Housz-Oro S, Joly P; Centre de R\u00e9f\u00e9rence des Maladies Bulleuses Auto-immunes (MALIBUL), et al. [Update of the French recommendations for the management of pemphigus]. Ann Dermatol Venereol. 2019;146(4):279-286. DOI: 10.1016\/j.annder.2019.01.018","DOI":"10.1016\/j.annder.2019.01.018"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Musette P, et al.; French Study Group on Autoimmune Bullous Skin Diseases. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040. DOI: 10.1016\/S0140-6736(17)30070-3","DOI":"10.1016\/S0140-6736(17)30070-3"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Rashid H, Lamberts A, van Maanen D, et al. The effectiveness of rituximab in pemphigus, and the benefit of additional maintenance infusions: daily practice data from a retrospective study. J Am Acad Dermatol. 2020;83(5):1503-1505. DOI: 10.1016\/j.jaad.2020.06.024","DOI":"10.1016\/j.jaad.2020.06.024"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/826\/1392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/826\/1392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T04:13:49Z","timestamp":1699157629000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6,7]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v68i1.826","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2021,6,7]]}}}